Favorable Regulatory and Reimbursement Frameworks Boost Lung Cancer Therapeutics Market Growth

Lung cancer therapeutics market was valued at $37,500 million in 2024 and is projected to reach $109,787 million by 2035, growing at a CAGR of 10.3% from 2025 to 2035. The market growth of innovative therapies is accelerated by FDA approval pathways, government-supported lung cancer screening programs, increased reimbursement coverage, and surrogate endpoints. For instance, in May 2025, the US FDA approved EMRELIS (Telisotuzumab Vedotin-Tllv) for adults with advanced non-small cell lung cancer (NSCLC) with high c-Met protein overexpression. It is approved by the overall response rate and duration of response. EMRELIS is a c-Met-targeted antibody-drug conjugate and the first and sole therapy ever approved for this patient population. NSCLC is the most common cause of cancer-related mortality globally, with 85% of lung cancer being identified as NSCLC.

Browse the full report description of “Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report by Cancer Type (Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC)), by Therapy Type (Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, and Others), and by End User (Hospitals, Cancer Research Institutes, Specialty Clinics, and Homecare Settings) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/lung-cancer-therapeutics-market

• In August 2024, the FDA approved lazertinib with amivantamab-vmjw for the initial treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as identified by an FDA-approved test.

• In October 2024, the FDA additionally approved Optune Lua as a treatment for use with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic non-small cell lung cancer who have progressed after a platinum-based regimen. The Phase 3 LUNAR study compared the use of Optune Lua concurrently with these inhibitors or docetaxel to PD-1/PD-L1 inhibitors or docetaxel alone. The primary endpoint showed a 3.3-month extension in median overall survival for patients treated with Optune Lua concurrently with a PD-1/PD-L1 inhibitor or docetaxel.

Market Coverage

• The market number available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035

• Segment Covered- 

o By Cancer Type

o By Therapy Type

o By End User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape - AstraZeneca PLC, Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Co., Novartis AG, Eli Lilly and Co., among others. 

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Lung Cancer Therapeutics Market Report Segment

By Cancer Type

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

By Therapy Type

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Radiation Therapy
• Others (Combination therapy, and Adjuvant/Neoadjuvant therapy)

By End User

• Hospitals
• Cancer Research Institutes
• Specialty Clinics
• Homecare Settings

Global Lung Cancer Therapeutics Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Russia

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Australia and New Zealand

• ASEAN Economies

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lung-cancer-therapeutics-market